BPC-157 in Interstitial Cystitis: A 12-Patient Pilot Study

This private-clinic pilot described symptom reports after a single procedure involving BPC-157 in 12 women with interstitial cystitis who had not responded to pentosan polysulfate.

Study design

Participants underwent cystoscopy and injections around areas of bladder inflammation. The investigators used a Global Response Assessment questionnaire after treatment; there was no placebo or comparator group.

What the researchers reported

Ten participants reported complete symptom resolution and two reported substantial but incomplete resolution. The abstract reported no dropouts or adverse events in this small cohort.

What this result does not establish

An uncontrolled 12-person pilot cannot separate treatment effects from placebo response, procedural effects, selection bias or measurement bias. It does not establish efficacy or general safety.

This article summarizes one published study about BPC-157. It does not establish clinical efficacy, general safety, regulatory approval or suitability for human use. Findings should be interpreted within the model, methods and limitations of the original paper.